BENCH TO CLINIC IN CONCURRENT CHEMORADIATION THERAPY

同步放化疗中的临床工作台

• 批准号: 6173569
• 负责人: HAK CHOY
• 金额: $ 10.29万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2004-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6173569
• 关键词: DNA topoisomerases; antineoplastics; carboplatin; clinical research; clinical trial phase I; combination cancer therapy; cytotoxicity; drug screening /evaluation; enzyme inhibitors; head /neck neoplasm; human subject; human therapy evaluation; irinotecan; laboratory mouse; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplastic cell; nonhuman therapy evaluation; nonsmall cell lung cancer; paclitaxel; pharmacokinetics; radiation dosage; radiosensitizer; topotecan

The principal investigator has a significant record in research that is both patient-oriented, and translational. A unique and important aspect of his career for the purposes of the K-24 Research Career Award is his continuous involvement with specific interventions beginning with pre-clinical work in the laboratory, and carrying through phases I, II, and III clinical trials. His primary research interest is in the study and development of new therapeutic agents that enhance the cell killing effects of radiation in cancer treatment. Current research projects involve bench studies of 4 agents that enhance the effects of radiation therapy-docetaxel, RFS-2000, RSR-13, and JM-216, all of which act by distinctly different mechanisms. Some studies involve a single agent and radiation therapy, while others involve a combination of chemotherapeutic agents together with radiation. Clinical studies involve three phase I studies of concurrent radiosensitizing agents and radiation therapy - docetaxel, irinotecan, and JM-216. One phase II study involves the allosteric modifier, RSR-13 and radiation therapy. All studies have been continuously supported through private pharmaceutical firm funding, and will continue to be so for the foreseeable future. He has initiated and stimulated a clinical research program in radiation oncology at the Vanderbilt Cancer Center, and was named Director of Clinical Research. Mentoring activities have been a consistent theme throughout his career, both at Brown University and at Vanderbilt. He initiated a fellowship program in radiation oncology clinical research using private funding, and has recruited 3 fellows into the program. Current mentoring activities involve 3 new faculty in the Vanderbilt Cancer Center. He initiated a mixed specialty symposium conference in concomitant chemoradiotherapy, which is continuing as a biennial conference. The K-24 Research Career Award will give the PI an opportunity to concentrate efforts on currently active clinical research projects, moving bench studies through to clinical trials, completing currently active clinical trials, and initiating studies on promising new agents.

首席研究员在以患者为导向和转化的研究中都有重要的记录。为了获得K-24研究职业奖，他的职业生涯中一个独特而重要的方面是，他从实验室的临床前工作开始，一直参与到具体的干预措施中，并进行了I、II和III期临床试验。他的主要研究兴趣是研究和开发新的治疗药物，以增强辐射在癌症治疗中的细胞杀伤作用。目前的研究项目包括4种增强放射治疗效果的药物——多西他赛、RFS-2000、RSR-13和JM-216，它们的作用机制截然不同。一些研究涉及单一药物和放射治疗，而另一些研究涉及化疗药物和放射治疗的组合。临床研究包括三个I期研究，同时使用放射增敏剂和放射治疗——多西他赛、伊立替康和JM-216。一项II期研究涉及变构调节剂、RSR-13和放射治疗。所有的研究都得到了私人制药公司的持续资助，在可预见的未来也将继续如此。他在范德比尔特癌症中心发起并推动了放射肿瘤学的临床研究项目，并被任命为临床研究主任。无论是在布朗大学（Brown University）还是范德比尔特大学（Vanderbilt），辅导活动一直是他职业生涯的主题。他发起了一个利用私人资金进行放射肿瘤学临床研究的奖学金项目，并招募了3名研究员。目前的指导活动涉及范德比尔特癌症中心的3名新教员。他发起了联合放化疗的混合专业研讨会，该会议将继续作为两年一次的会议。K-24研究事业奖将使PI有机会将精力集中在当前活跃的临床研究项目上，将实验室研究转移到临床试验，完成当前活跃的临床试验，并启动有前景的新药研究。